Morningstar

MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft ...

aGvHD is a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. The patients (N=173) treated in EAP previously failed 1 to 6 aGvHD systemic treatment ...
Business Wire

MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies ...
Nasdaq

Monopar Therapeutics Announces FDA Authorization for Expanded Access Program of Investigational Agents MNPR-101-Zr and MNPR-101-Lu in Collaboration with Excel Diagnostics

The FDA has authorized the Expanded Access Program (EAP) for the investigational imaging agent MNPR-101-Zr and therapeutic agent MNPR-101-Lu, allowing patients with advanced solid tumors access to ...